Virtus ETF Advisers LLC Athira Pharma, Inc. Transaction History

Virtus ETF Advisers LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $275 - $372	94 Added 0.73%	13,008 $39,000
Q2 2022 Aug 12, 2022	BUY	$2.74 - $13.43 $3,707 - $18,170	1,353 Added 11.7%	12,914 $39,000
Q1 2022 May 16, 2022	SELL	$8.96 - $13.51 $6,164 - $9,294	-688 Reduced 5.62%	11,561 $156,000
Q4 2021 Feb 14, 2022	BUY	$9.17 - $16.39 $11,856 - $21,192	1,293 Added 11.8%	12,249 $160,000
Q3 2021 Nov 15, 2021	SELL	$9.15 - $11.09 $5,252 - $6,365	-574 Reduced 4.98%	10,956 $103,000
Q2 2021 Aug 10, 2021	BUY	$10.24 - $20.87 $118,067 - $240,631	11,530 New	11,530 $118,000

16.8M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $18.9M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.